Article mayhem
   
Nav Menu
select
home
select
Sign up
select
Login
select
Submit Articles
select
Submission Guidelines
select
Top Articles
select
Link Directory
select
About Us
select
Contact Us
select
Privacy Policy
select
RSS Feeds
 
Categories

Accessories
Arts
Business
Cars and Trucks
CGI
Coding Sites
Computers
Cooking
Crafts
Current Affairs
Databases
Entertainment
Film
Finances
Gardening
Healthy Living
Holidays
Home
Internet
Medical
Men Only
Motorcyles
Our Pets
Outdoors
Relationships
Religion
Self Improvement
Sports
Staying Fit
Technology
Travel
Web Design
Weddings
Women Only
Writing
 
Stats
Total Articles: 519629
Total Authors: 142199
Total Downloads: 20359322


Newest Member
Patrick Winter

 


   

Female Hypoactive Sexual Desire Disorder - Hormonal Treatment


Testosterone

Long-term data for safety and benefit of testosterone therapy in women are lacking, but such data are necessary before long-term practice of testosterone can be recommended. Likewise, safety data for the utilisation of testosterone in nonestrogen substituted postmenopausal women are lacking and no recommendation for its practice can be made currently. Nor can the supplementation of T to premenopausal women be urged until such time there exist safety and efficacy data. Unluckily, any enduring benefit after short-term treatment, although theoretically potential, is unproven. In addition, supplementing T on a temporary basis only, could have adverse consequences on the couple if an improvement connected with T therapy is no longer apparent when it is withdrawn.

If despite the above, T supplementation is contemplated, careful assessment must render absence of ongoing psychological (interpersonal, intrapersonal, contextual, and societal) or physical factors negatively affecting sexual desire and arousability. On the basis of available data, no specific testosterone regime or dose can yet be recommended. The chosen formulation of testosterone must have pharmacokinetic data pointing that it produces blood levels within the normal premenopausal range. Accomplishing physiological free testosterone levels by transdermal delivery appears to be the best approach.

Contraindications to testosterone therapy include androgenic alopecia, seborrhea, or acne, hirsutism as well as a history of polycystic ovary syndrome, and estrogen depletion. Oral methyl testosterone therapy is contraindicated in women with hyperlipidemia or liver dysfunction. Regular follow up is both clinical inspection of skin and hair for seborrhea, acne, hirsutism, and alopecia and biochemical through monitoring of free/bioavailable testosterone and SHBG, keeping these values within the normal range for premenopausal women. Of note, methyl-T is not included in the common assays for T. Possibly, the target level for older women should be even lower but this stays obscure. Lipid profile and glucose tolerance are also monitored. The current recommendation is to prescribe only for 12 months owing to lack of long-term safety data.

Tibolone

Tibolone is a synthetic steroid with tissue selective estrogenic, progestogenic, and androgenic actions. In usage in Europe for more than 10 years, tibolone allows some relief from vasomotor symptoms, estrogen agonist activity on the vagina and bone, but not on the endometrium. Tibilone was thought not to have estrogen agonist activity on breast tissue; but a recent, albeit nonrandomized but very large study of postmenopausal hormonal therapy showed a similar increase in breast cancer in women receiving tibolone and those receiving various combinations of estrogen and progestins. The typical (presumed beneficial) estrogenic results on lipids are not seen, but it is of note that tibolone does not promote (unwanted) coagulation. Prospective randomized trials comparing tibolone to placebo or to various formulations of estrogen and progestin therapy have been done. Although in most but not all, there was substantial improvement in sexual desire in the women receiving tibolone; no study focused on sexually dysfunctional women. Recruitment centered on vasomotor symptoms or bone density. Studies in postmenopausal women with loss of arousability and therefore of sexual desire are needed.



Author Resource:- David Crawford is the CEO and owner of a matters of size penis enlargement company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of vigrx plus This article may be freely distributed if this resource box stays attached.

[Valid RSS feed]  Category Rss Feed - http://www.articlemayhem.com/rss.php?rss=88
By : David Jamesonsess    29 or more times read
Submitted 2010-07-02 20:36:33
Article From Article Mayhem

ezine ready view Ezine ready view

Related Articles

 
 


[Valid RSS feed]